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Introduction Polymyxin B-direct hemoperfusion (PMX-DHP) 
(Toraymyxin®; Toray Medical Co., Tokyo, Japan) has been approved to 
treat patients with endotoxemia and/or severe sepsis due to Gram-
negative infection since 1994 in Japan. However, its effi  cacy and 
indication are still controversial. Recently, randomized controlled 
studies were performed in other countries. Our hypothesis is that 
PMX-DHP may be useful for emergency-operated patients to eliminate 
endotoxins from the systemic circulation after removal of the source 
of infection.
Methods From July 1994 to May 2011, all adult patients treated with 
PMX-DHP in our ICU were included in this retrospective observational 
study. Patients’ clinical and microbiological data were collected 
from medical archives. The emergency postoperation patients and 
the medical patients were compared for severity, mortality, and 
hemodynamic status. Values are expressed as mean  ±  SD. Data were 
analyzed by Mann–Whitney U test, chi-square test and Fisher’s exact 
probability test. P <0.05 was considered statistically signifi cant.
Results One hundred and sixty-six patients (98 men, 68 women; age 
range 24 to 92 years (mean 64.7 ± 13.3)) were studied. The mortality rate 
was 34.9% at 28 days after PMX-DHP. There were 129 (77.7%) emergency 
surgical patients and 37 (22.3%) medical patients. The APACHE II score 
on the day of PMX-DHP was not signifi cantly diff erent between surgical 
and medical patients (20.3 ± 7.0 vs. 19.2 ± 8.1, P = 0.417). Mean arterial 
pressure (MAP) signifi cantly improved in emergency surgical patients 
before and after PMX-DHP therapy (73.7 ± 24.8 vs. 79.7 ± 26.0 mmHg, 
P = 0.017), while MAP was not statistically diff erent in medical patients 
(69.7 ± 24.2 vs. 76.7 ± 27.1 mmHg, P = 0.178). The inotropic score had 
no statistical diff erence between before and after PMX-DHP in both 
surgical and medical patients (13.2  ±  19.8 vs. 12.6  ±  19.2, P  =  0.61; 
16.8 ± 27.3 vs. 13.8 ± 23.6, P = 0.65, respectively). The mortality rates at 
28 days, 90 days, 0.5 year and 1 year after PMX-DHP were signifi cantly 
diff erent between surgical and medical patients (28.7 vs. 56.8, 43.8 vs. 
83.3, 52.2 vs. 85.7, 54.5 vs. 91.2%, P <0.0001, respectively).
Conclusion MAP increased in surgical patients but did not change 
in medical patients after PMX-DHP, and the inotropic score was not 
signifi cantly diff erent in both sets of patients. The mortality was 
signifi cantly lower in surgical patients than in medical patients.
P383
Clinical impact of enhanced cytokine clearance with sustained high-
effi  ciency daily diafi ltration using a mediator-adsorbing membrane 
(SHEDD-fA) in patients with severe sepsis
O Nishida1, T Nakamura1, N Kuriyama1, K Moriyama1, T Miyasho2, 
S Yamada3
1Fujita Health University School of Medicine, Toyoake, Japan; 2Rakuno Gakuen 
University, Ebetsu, Japan; 3Shino-Test Corporation, Sagamihara, Japan
Critical Care 2012, 16(Suppl 1):P383 (doi: 10.1186/cc10990)
Introduction SHEDD-fA is an eff ective modality that makes the best 
use of three principles in the treatment of severe sepsis: diff usion, 
convection and adsorption. We reported the effi  cacy of SHEDD-fA for 
the treatment of severe sepsis at the 31st ISICEM 2011 [1]. Here we 
present the blood clearance (CL) of seven important cytokines with 
SHEDD-fA.
Methods Ten critically ill patients were studied who were on SHEDD-
fA, at QB  =  150 ml/minute, QF  =  1,500 ml/hour (post dilution) and 
QD  =  300 to 500 ml/minute as a nonrenal indication. In order to 
maximize cytokine adsorption effi  ciency, we used a large-size (2.1 m2) 
PMMA dialyzer. Blood samples were taken to measure the CL of plasma 
cytokines (HMGB-1, IL-6, IL-8, IL-10, G-CSF, MCP-1 and MIP-1) at 1 hour 
and 3 hours after initiation (in one cytokine by 62 to 107 samples).
Results The median values of CL with interquartile ranges of each 
cytokine (molecular weight: kDa) were: HMGB1 (30 kDa), 53.1 ml/
minute (2.1 to 12.5); IL-6 (21 kDa), 39.9 ml/minute (12.4 to 70.6); IL-8 
(8 kDa), 64.1 ml/minute (–0.5 to 82.0); IL-10 ml/minute (35 to 40 kDa), 
45.6 ml/minute (0.5 to 88.3); G-CSF (19 kDa), 33.2 ml/minute (9.3 to 
60.8); MCP-1 (8.7 kDa), 68.5 ml/minute (–14.4 to 125.4); and MIP-1 (7.8 
kDa), 66.5 ml/minute (18.6 to 100.0). In particular, CL of HMGB1 was 
positively correlated with pre-SHEDD-fA blood levels, indicating the 
mechanism of HMGB1 removal was through adsorption. As a result of 
enhancing the intensity of the dosage, CL (53 ml/minute) of HMGB1 
was higher than that (25 ml/minute) of an in vitro experiment that we 
reported at the 31st ISICEM 2011. See Figure 1.
Conclusion Taking into account the fact that the creatinine CL of native 
kidney function is 100 ml/minute, our fi ndings suggest that SHEDD-fA 
is a feasible adjusted modality for the treatment of patients with severe 
sepsis, with or without acute kidney injury. Considering our other 
laboratory fi ndings, deep fi ltration may enhance blood clearance.
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Figure 1 (abstract P383). Correlation between clearance and blood level of cytokines.
Critical Care 2012, Volume 16 Suppl 1 
http://ccforum.com/supplements/16/S1
S137
